Regencell Bioscience Holdings Limited Ordinary Shares RGC
i
Market datapartial · fetched 2026-11-04T04:21:28.619Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T22:35:52.167276548Z
FundamentalsAlpha Vantage · unavailable
Regencell Bioscience Holdings Limited Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.23 | 141.7% | 22.0% | |||
| 25Δ | 5.64 | 172.0% | 21.6% | |||
| 30Δ | 6.05 | 202.3% | 21.1% | |||
| 35Δ | 6.46 | 232.6% | 20.7% | |||
| 40Δ | 6.86 | 262.9% | 20.2% | |||
| 45Δ | 7.27 | 293.2% | 19.7% | |||
| 50Δ | 7.65 | 302.4% | 18.5% | |||
| 55Δ | 7.98 | 284.9% | 16.1% | |||
| 60Δ | 5.91 | 298.3% | 22.5% | 8.32 | 267.5% | 13.8% |
| 65Δ | 5.61 | 326.4% | 21.6% | 8.65 | 250.0% | 11.5% |
| 70Δ | 5.31 | 354.6% | 20.8% | 8.99 | 232.5% | 9.2% |
| 75Δ | 5.00 | 382.7% | 20.0% | 9.32 | 215.0% | 6.9% |
| 80Δ | 9.65 | 197.6% | 4.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.23
- IV
- 141.7%
- B/E move
- 22.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.64
- IV
- 172.0%
- B/E move
- 21.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.05
- IV
- 202.3%
- B/E move
- 21.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.46
- IV
- 232.6%
- B/E move
- 20.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.86
- IV
- 262.9%
- B/E move
- 20.2%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.27
- IV
- 293.2%
- B/E move
- 19.7%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.65
- IV
- 302.4%
- B/E move
- 18.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.98
- IV
- 284.9%
- B/E move
- 16.1%
60Δ
- Pseudo strike
- 5.91
- IV
- 298.3%
- B/E move
- 22.5%
- Pseudo strike
- 8.32
- IV
- 267.5%
- B/E move
- 13.8%
65Δ
- Pseudo strike
- 5.61
- IV
- 326.4%
- B/E move
- 21.6%
- Pseudo strike
- 8.65
- IV
- 250.0%
- B/E move
- 11.5%
70Δ
- Pseudo strike
- 5.31
- IV
- 354.6%
- B/E move
- 20.8%
- Pseudo strike
- 8.99
- IV
- 232.5%
- B/E move
- 9.2%
75Δ
- Pseudo strike
- 5.00
- IV
- 382.7%
- B/E move
- 20.0%
- Pseudo strike
- 9.32
- IV
- 215.0%
- B/E move
- 6.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.65
- IV
- 197.6%
- B/E move
- 4.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 193.68% | |
| 215.73% |
Drug Manufacturers - Specialty & Generic
SCYX
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
More →SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered…
More →SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous…
More →TAK
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer…
More →TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North…
More →TKNO
Description unavailable
More →